Africa presents enormous opportunities for growth in the pharmaceutical industry as drug spending is expected to hit $30 billion by 2016, up from $8 billion in 2010. Many African nations are experiencing rapid economic and demographic changes including growing urban populations and increasing rates of non-communicable diseases. However, Africa faces challenges such as a fragmented regulatory system and over-reliance on imported drugs. Initiatives are underway to boost local pharmaceutical manufacturing and harmonize drug regulations across Africa to facilitate industry growth and better serve patient needs on the continent.
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Presentation by Adil Zanfari, President, Genpharma, Morocco made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
13th Cairo marketing Club (Egyptian Pharma Market ) by Dr.Haytham MareiMahmoud Bahgat
13th Cairo marketing Club (Egyptian Pharma Market ) by Dr.Haytham Marei
*#Mahmoud_Bahgat*
*#Marketing_Club*
للاشتراك في نادي التسويق بالشرق الاوسط
*If you are a Marketer now*
To Join our whatsapp &Monthly Meeting in Middle East Cities
Send me ur data on Whatsap
00966569654916
*Fill ur data here as speaker or member*
https://lnkd.in/efkTE7T
Join now
*Marketing Club Facebook Page*
https://lnkd.in/gm4c4hD
*Marketing Club Facebook Group*
https://lnkd.in/gX-5au5
*Egyptian Pharmacists Society Facebook Page*
https://lnkd.in/fucnv_5
•••••••••••••••••••••••••••••
*#Mahmoud_Bahgat*
00966568654916
لخدمات التسويق والدعاية والاعلان
*#Legendary_ADLAND*
Complete Marketing Solutions
*www.LegendaryADLAND.com*
•••••••••••••••••••••••••••••
للحصول على اقامة او شركة في اوروبا
*#Legendary_Europe*
Europe Companies & Residency
*www.LegendaryEurope.info*
•••••••••••••••••••••••••••••
*Contact Bahgat*
M.Bahgat@TheLegendary.Info
The presentation discuss the size of the generic market in the Middle East and defining Jordan as a location suitable and attractive to put manufacturing plants.
The statistics also include health spending by country
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
Introduction to indian pharma industriespharmacampus
Introduction to Indian Pharma Industries: this highlights leading pharma producers, details of exports of medicines, growth statistics, and high potential generic market.
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
The Growing Pharmaceutical Business in Latin America. By Fernando Ferrer. Mul...Fernando Ferrer, MBA
Presentation at the Meadowlands Chamber of Commerce. NJ, USA
Fernando Ferrer, MBA - October 30, 2013
The challenges of the Pharmaceutical business in Latin America
The global pharmaceutical retail market is forecasted to reach US$ 1.2 trillion by 2017.
The 33 Latin American countries when taking together possess certain regional common characteristics in their political, geographical, socio-economic, racial and cultural profile; but many peculiarities and differences that range from infrastructure to local regulations and market access, all of which must be understood in order to create and implement business strategies to capture the market of 600 million people.
Brazil, Mexico, Argentina and Venezuela rank already on the top 20 worldwide pharma markets. At a Compound Annual Growth Rate (CAGR) of 12% in 5 years, the sales forecast of the top 7 Latin American markets will reach close to US$ 110 billion, boosting the growth of other regional countries and life science markets.
During the presentation we will discuss on key factors to succeed when entering in these growing markets.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
Next Evolutionary Wave. The New Walmart Hard Lines On-line DeliveryWayne Hale
IsicorpBPM, also has an open purchase order commercial contract account with the Walmart Corporation. Desire to negotiate executing a Web/ mobile on-line, on-site assembly and delivery services for AAFES and Walmart registered customers.
13th Cairo marketing Club (Egyptian Pharma Market ) by Dr.Haytham MareiMahmoud Bahgat
13th Cairo marketing Club (Egyptian Pharma Market ) by Dr.Haytham Marei
*#Mahmoud_Bahgat*
*#Marketing_Club*
للاشتراك في نادي التسويق بالشرق الاوسط
*If you are a Marketer now*
To Join our whatsapp &Monthly Meeting in Middle East Cities
Send me ur data on Whatsap
00966569654916
*Fill ur data here as speaker or member*
https://lnkd.in/efkTE7T
Join now
*Marketing Club Facebook Page*
https://lnkd.in/gm4c4hD
*Marketing Club Facebook Group*
https://lnkd.in/gX-5au5
*Egyptian Pharmacists Society Facebook Page*
https://lnkd.in/fucnv_5
•••••••••••••••••••••••••••••
*#Mahmoud_Bahgat*
00966568654916
لخدمات التسويق والدعاية والاعلان
*#Legendary_ADLAND*
Complete Marketing Solutions
*www.LegendaryADLAND.com*
•••••••••••••••••••••••••••••
للحصول على اقامة او شركة في اوروبا
*#Legendary_Europe*
Europe Companies & Residency
*www.LegendaryEurope.info*
•••••••••••••••••••••••••••••
*Contact Bahgat*
M.Bahgat@TheLegendary.Info
The presentation discuss the size of the generic market in the Middle East and defining Jordan as a location suitable and attractive to put manufacturing plants.
The statistics also include health spending by country
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
Introduction to indian pharma industriespharmacampus
Introduction to Indian Pharma Industries: this highlights leading pharma producers, details of exports of medicines, growth statistics, and high potential generic market.
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
The Growing Pharmaceutical Business in Latin America. By Fernando Ferrer. Mul...Fernando Ferrer, MBA
Presentation at the Meadowlands Chamber of Commerce. NJ, USA
Fernando Ferrer, MBA - October 30, 2013
The challenges of the Pharmaceutical business in Latin America
The global pharmaceutical retail market is forecasted to reach US$ 1.2 trillion by 2017.
The 33 Latin American countries when taking together possess certain regional common characteristics in their political, geographical, socio-economic, racial and cultural profile; but many peculiarities and differences that range from infrastructure to local regulations and market access, all of which must be understood in order to create and implement business strategies to capture the market of 600 million people.
Brazil, Mexico, Argentina and Venezuela rank already on the top 20 worldwide pharma markets. At a Compound Annual Growth Rate (CAGR) of 12% in 5 years, the sales forecast of the top 7 Latin American markets will reach close to US$ 110 billion, boosting the growth of other regional countries and life science markets.
During the presentation we will discuss on key factors to succeed when entering in these growing markets.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
Next Evolutionary Wave. The New Walmart Hard Lines On-line DeliveryWayne Hale
IsicorpBPM, also has an open purchase order commercial contract account with the Walmart Corporation. Desire to negotiate executing a Web/ mobile on-line, on-site assembly and delivery services for AAFES and Walmart registered customers.
Active matrix organic light emitting diode
(AMOLED) displays are considerably attractive for high
brightness, high efficiency and fast response time. Active
matrix employing thin Film Transistors (TFTs) allows
OLED displays to be larger in size, higher in resolution
and lower in power consumption than passive matrix.
Especially, low temperature polycrystalline silicon
(LTPS) TFT employing excimer laser annealing (ELA) is
widely used due to high mobility and high stability. A
number of TFT active matrix pixel circuits have been
developed in order to compensate for TFT parameter
variations due to the fluctuation of excimer laser energy.
We discuss various compensation schemes of LTPS TFT
pixel circuits.
Keywords: AMOLED; poly-Si TFT; pixel
Please read below case and individually take the role of “NGOsAdvoc.pdfpallavi953613
Please read below case and individually take the role of “NGOs/Advocacy Groups” as one of the
important stakeholder.
Discuss the case, from your chosen stakeholder as “NGOs/Advocacy Groups” and perspective
analyzing the reasons for the current situation and the changes you would propose for the future,
supported with additionally researched relevant information.
Please mention your list of references and at least 400 words.
In-Depth Integrative Case 1.2
Pharmaceutical Companies, Intellectual Property,
and the Global AIDS Epidemic
In August 2003, after heavy lobbying from nongovernmental
organizations (NGOs) such as Doctors Without
Borders, the U.S. pharmaceutical industry finally dropped
its opposition to relaxation of the intellectual property
rights (IPR) provisions under World Trade Organization
(WTO) regulations to make generic, low-cost antiviral
drugs available to developing countries like South Africa
facing epidemics or other health emergencies. 1 Although
this announcement appeared to end a three-year dispute
between multinational pharmaceutical companies, governments,
and NGOs over the most appropriate and effective
response to viral pandemics in the developing world, the
specific procedures for determining what constitutes a
health emergency had yet to be worked out. Nonetheless,
the day after the agreement was announced, the government
of Brazil said it would publish a decree authorizing
imports of generic versions of patented AIDS drugs that
the country said it could no longer afford to buy from
multinational pharmaceutical companies. Although the
tentative WTO agreement would appear to allow such
production under limited circumstances, former U.S. trade
official Jon Huenemann remarked, “They’re playing with
fire. . . . The sensitivities of this are obvious and we’re
right on the edge here.”
Despite the role of developed and developing country
governments, NGOs, large pharmaceutical companies,
and their generic competitors in crafting this agreement,
it was unclear how it would be implemented and whether
action would be swift enough to stem the HIV/AIDS epidemic
ravaging South Africa and many other countries.
The AIDS Epidemic and Potential
Treatment
In 2008, after over two decades of fighting the AIDS epidemic
and raising the public awareness, HIV/AIDS still
remained one of the leading causes of death in the world,
occupying the 6th position in WHO Top 10 Causes of
Death list. 3 According to the World Health Organization
(WHO), in 2008 there were approximately 33.4 million
people living with AIDS, with 2.7 million newly infected,
and 2 millions deaths (see Table 1). Since 1980, AIDS has
killed more than 25 million people. HIV is especially
deadly because it often remains dormant in an infected person
for years without showing symptoms and is transmitted
to others often without the knowledge of either person. HIV
leads to AIDS when the virus attacks the immune system
and cripples it, making the person vulnerable to diseases. 4
Th.
The Africa healthcare landscape has many issues from lack of physicians to drug availabilities. However the emergence of less expensive drugs and the mobile phone boom on the continent open new solutions areas for African countries
Target Market - A continent rich in prospects and enthusiasm, Africa could ha...PharmaAfrica
European Biopharmaceutical Review talks to PharmaAfrica about the vibrant and wide-ranging opportunities on offer for pharma companies looking to expand into new directions. July 2015 edition
Pharmaceutical Market in Iran - Opportunities and Market AccessEirhub
Iran Pharmaceutical Market - opportunities and market access. From its well-educated workforce to its dynamic competitive landscape, the Iranian pharmaceutical market has much to offer new entrants (The report is developed by Roland Berger)
Zoonotic diseases is the rare disease that is usually spread from faunas to humans and from humans to faunas. There are various ways of disease being transferred, such as air by direct contact, by contact with an inert object that harbors the disease, oral ingestion, and by insect. The diseases from wiretaps and other faunas can make sick or death in people. Many health agencies globally have track on the disease and death caused by zoonotic disease. The animals always carry some or the other infective pathogens that can be shared or transmitted with/ to people. Zoonotic diseases may be caused by germs which including bacteria, viruses, parasites, and fungi. Zoonoses when infected can lead to many different types of illnesses in humans and faunas which can be mild to severe that human or animal may die. It is always important to notice that the faunas do not always appear ill or sick when carrying a zoonotic disease, many animals do appear healthy, but they still carry infectious germs that can make people sick.
Zoonotic diseases has become very common now a days throughout the globe. Scientist’s assessment about the zoonotic diseases are that more than 8 out of every 12 known infectious diseases in humans are spread from faunas, and 4 out of every 5 new or emerging infectious diseases in people are spread from faunas. Yearly, estimated, thousands of Americans gets sick from diseases spread between faunas and humans. Because of this, the national health agency works 24/7 to protect people from zoonotic diseases.
Industry Coverage Report on Indian Pharmaceuticals Sector which encapsulates the structure, drivers, key trends, concentration and current scenario. Prepared by me in association with the Alpha Investment & Research Club, FMS Delhi.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
Development Challenges, South-South Solutions is the monthly e-newsletter for the United Nations Development Programme’s South-South Cooperation Unit (www.southerninnovator.org). It has been published every month since 2006.
Stories by David South
Design and Layout: UNDP South-South Cooperation Unit
3rd annual pharmaceutical leadership summit 2014 white paper Indian Affairs
It is widely believed that the consolidations in the Indian pharma sector is likely to continue, particularly among generic drug players and will drive shareholder value going forward.India-based pharmaceutical companies have majorly been absent from much of the recent M&A activities, partly because of their healthy growth outlooks. The global pharmaceutical industry will continue to undergo a pace of rapid consolidation to drive shareholder value; particularly in the case of companies seeking new growth platforms, against the backdrop of patent expirations.With many drugs going off patent in the US, Indian pharma companies would continue to experience strong growth in American market, indian pharma companies would continue to experience strong growth in the US over the medium-term. This would be driven by the sizable generic opportunity (drugs with brand value of $25-30 billion are expected to face generic competition) over the next 2-3 years. As one of the recently industrialized nations, India has a fast-growing economy as well as an ever-expanding, ever-urbanized population, however its healthcare system still has a lot of potential for development. To Western readers, analyzing a healthcare system in the East seems daunting. It takes some of us decades to master an understanding of the healthcare system of our origin country. Nevertheless, there are several methods to approaching another country’s system. These include the exposition of some invariant principles that apply across various contexts, the application of existing frameworks for healthcare system analysis, appraisal of the major transitions underway in the country, and an analysis of the country’s public health issues. India faces challenges in pursuing each of these goals. With regards to cost, at least 70% of all healthcare is frequently financed out-of-pocket by the population. There is little health insurance or other forms of risk pooling, little regulation and accountability of providers, and a predominance of fee-for-service payment, all of which are associated with high costs. There is also questionable efficiency of much of the state healthcare system, and a great distrust of the public sector. Against the backdrop of the above challenges, Pharmaleaders has lined up top industry experts, Pharma Academia, Ministry Officials, Government Representative, Policy Makers & Medical Professionals under one platform both in india & abroad to debate & deliberate the complex issues of the industry & give a meaningful discussion on the Brand India & Make In India concept. More than 300 professionals will be participating the mega event where professionals from Middle East, Africa, Europe, Lation America will also be attending.The historic 7th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2014 to be held in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructur
Successfully Accessing Medical Equipment Markets in CIVETS Available on Rese...QYResearchReports
The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.